Vincera Pharma Inc

VINC | $0.9392 -1.14% -1.15% 460K

(0.0% 1d) (-80.8% 1m) (-22.8% 1y) (0.0% 2d) (9.2% 3d) (11.8% 7d) (29.5% volume)
Earnings Calendar:
Market Cap: $ 20,111,455
https://vincerx.com
Sec Filling | Patents | 28 employees

Vincerx Pharma (Vincerx) is a recently formed clinical-stage life sciences company focused on leveraging its extensive development and oncology expertise to advance new therapies intended to address unmet medical needs for the treatment of cancer. Vincerx’s executive team has assembled a management team of biopharmaceutical experts with extensive experience in building and operating organizations that develop and deliver innovative medicines to patients. Vincerx’s current pipeline is derived from an exclusive license agreement with Bayer and includes a clinical-stage and follow-on small molecule drug program and a preclinical stage bioconjugation/next-generation antibody-drug conjugate platform. The company intends to develop multiple products through clinical proof-of-concept and potentially through Accelerated Approval in the United States.

cancer treatment antibody molecule drugs

add to watch list Paper trade email alert is off

Press-releases

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-08 (Crawled : 21:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| -80.13% | O: -65.69% H: 0.84% C: -35.37%
vip236 pharma association positive cancer pipeline research for meeting

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-04-01 (Crawled : 12:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| -83.41% | O: -14.59% H: 21.68% C: 19.63%
vip236 association cancer research meeting

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Published: 2024-03-29 (Crawled : 20:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| Email alert Add to watchlist
pharma year update financial results

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| -82.82% | O: 16.64% H: 21.55% C: 8.99%
association cancer research meeting

Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
Published: 2024-01-07 (Crawled : 20:20) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| -19.49% | O: 38.56% H: 4.59% C: -16.82%
pharma

Vincerx Pharma Presents Preclinical VIP943 and VIP924 Posters at ASH 2023
Published: 2023-12-10 (Crawled : 20:20) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| Email alert Add to watchlist
vip943 pharma vip924 preclinical

Vincerx Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Published: 2023-11-14 (Crawled : 12:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| 8.08% | O: -1.02% H: 3.39% C: -8.05%
pharma update financial results

Vincerx Pharma To Present Three Posters at ASH 2023 in December
Published: 2023-11-02 (Crawled : 13:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| 4.97% | O: 4.42% H: 2.38% C: -1.3%
pharma

Vincerx Pharma to Participate at the Cantor Fitzgerald Global Healthcare Conference 2023
Published: 2023-09-19 (Crawled : 11:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| 6.86% | O: 4.05% H: 0.0% C: -0.65%
pharma conference global

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943
Published: 2023-09-14 (Crawled : 11:00) - globenewswire.com
VINC | $0.9392 -1.14% -1.15% 460K

| 26.67% | O: 6.93% H: 0.0% C: -0.47%
vip943 pharma trial

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-028866	4	2024-03-09	2024-03-07	Buy	A	123750	123750
0000950170-24-028865	4	2024-03-09	2024-03-07	Buy	A	93750	93750
0000950170-24-028856	4	2024-03-09	2024-03-07	Buy	A	93750	93750